A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies (NCT03888105)
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab. The study is looking at several other research questions, including: * To see if odronextamab works to destroy cancer cells * Side effects that may be experienced by people taking odronextamab * How odronextamab works in the body * How much odronextamab is present in the blood
Who can join: Review the eligibility criteria below.
Location: Rush University Medical Center — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (119 Sites)
Showing the first 25 of 119 sites.
- Rush University Medical Center — Chicago, Illinois
- University of Iowa — Iowa City, Iowa
- Norton Cancer Institute — Louisville, Kentucky
- Tufts Medical Center — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Mayo Clinic - Rochester — Rochester, Minnesota
- John Theurer Cancer Center at Hackensack UMC — Hackensack, New Jersey
- Weill Cornell Medical College New York Presbyterian Hospital — New York, New York
- Stony Brook University Hospital — Stony Brook, New York
- Wake Forest Baptist Medical Center — Winston-Salem, North Carolina
- Cleveland Clinic Foundation — Cleveland, Ohio
- Stephenson Cancer Center — Oklahoma City, Oklahoma
- Harold C. Simmons Comprehensive Cancer Center — Dallas, Texas
- Border Medical Oncology — East Albury, New South Wales
- Northern NSW Local Health District The Tweed Hospital — Tweed Heads, South Wales
- Epworth Hospital — East Melbourne, Victoria
- North Building — Frankston, Victoria
- Andrew Love Cancer Centre — Geelong, Victoria
- Olivia Newton John Cancer Wellness & Research Centre — Heidelberg, Victoria
- Royal Perth Hospital — Perth, Western Australia
- Cross Cancer Institute — Edmonton, Alberta
- QEII Health Science Centre - Halifax location — Halifax, Nova Scotia
- Peking University Cancer Hospital (Beijing Cancer Hospital) (Beijing Institute for Cancer Research) — Beijing, Beijing Municipality
- Peking Union Medical College Hospital — Beijing, Beijing Municipality
- Institute of Hematology & Blood Diseases Hospital — Tianjin, Beijing Municipality
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in B-cell Non-Hodgkin Lymphoma (B-NHL)
- Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma — Chicago, Illinois
- A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma — Ciudad Autonoma de Buenos Aires, Buenos Aires
- Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies — Miami, Florida
Explore by condition: All B-cell Non-Hodgkin Lymphoma (B-NHL) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.